March 30 (Reuters) - Patients are finally starting to reap some of the benefits of personalized medicine as drug and diagnostic companies begin to use newly-acquired genetic information to develop so-called companion diagnostics -- tests used to tailor drugs to a patient’s specific genetic makeup.
